HighTower Advisors LLC Sells 56,467 Shares of Boston Scientific Corporation $BSX

Posted by George Bondi on Sep 11th, 2026

Boston Scientific logo HighTower Advisors LLC decreased its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 26.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 153,501 shares of the medical equipment provider’s stock after selling 56,467 shares during the period. HighTower Advisors LLC’s holdings in Boston Scientific were worth $6,551,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $26,000. Sfam LLC bought a new position in Boston Scientific during the 4th quarter worth approximately $29,000. Finally, South Plains Financial Inc. bought a new position in Boston Scientific during the 4th quarter worth approximately $39,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on BSX shares. TD Cowen reaffirmed a “buy” rating and issued a $56.00 target price on shares of Boston Scientific in a research note on Tuesday, August 25th. Canaccord Genuity Group reduced their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a report on Wednesday, July 29th. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, BTIG Research dropped their price objective on Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research note on Wednesday. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $71.46.

View Our Latest Research Report on Boston Scientific

Boston Scientific Stock Down 4.3%

Shares of Boston Scientific stock opened at $43.03 on Friday. The firm has a market cap of $62.36 billion, a PE ratio of 17.42, a P/E/G ratio of 1.04 and a beta of 0.57. The business’s 50 day simple moving average is $47.04 and its 200 day simple moving average is $54.74. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $105.72.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.